170 related articles for article (PubMed ID: 19471183)
1. Yi-gan san as adjunctive therapy for treatment-resistant schizophrenia: an open-label study.
Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
Clin Neuropharmacol; 2009; 32(1):6-9. PubMed ID: 19471183
[TBL] [Abstract][Full Text] [Related]
2. Yi-gan san for the treatment of borderline personality disorder: an open-label study.
Miyaoka T; Furuya M; Yasuda H; Hayashia M; Inagaki T; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):150-4. PubMed ID: 17765378
[TBL] [Abstract][Full Text] [Related]
3. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
[TBL] [Abstract][Full Text] [Related]
4. Yi-gan san for treatment of charles bonnet syndrome (visual hallucination due to vision loss): an open-label study.
Miyaoka T; Furuya M; Kristian L; Wake R; Kawakami K; Nagahama M; Kawano K; Ieda M; Tsuchie K; Horiguchi J
Clin Neuropharmacol; 2011; 34(1):24-7. PubMed ID: 21164340
[TBL] [Abstract][Full Text] [Related]
5. [Clinical usage of Yi-gan san-schizophrenia, borderline personality disorder, dyskinesia etc-].
Horiguchi J
Seishin Shinkeigaku Zasshi; 2012; 114(6):708-18. PubMed ID: 23094294
[TBL] [Abstract][Full Text] [Related]
6. Effect of Yi-Gan San on psychiatric symptoms and sleep structure at patients with behavioral and psychological symptoms of dementia.
Shinno H; Inami Y; Inagaki T; Nakamura Y; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):881-5. PubMed ID: 18243460
[TBL] [Abstract][Full Text] [Related]
7. Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.
Potvin S; Stip E; Lipp O; Elie R; Mancini-Marië A; Demers MF; Roy MA; Bouchard RH; Gendron A
Curr Med Res Opin; 2006 Jul; 22(7):1277-85. PubMed ID: 16834826
[TBL] [Abstract][Full Text] [Related]
8. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].
György B; Robert K; László C; Andrea J;
Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
Lee KU; Jeon YW; Lee HK; Jun TY
Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
[TBL] [Abstract][Full Text] [Related]
10. Traditional Chinese medicine on four patients with Huntington's disease.
Satoh T; Takahashi T; Iwasaki K; Tago H; Seki T; Yaegashi N; Tobita M; Arai H
Mov Disord; 2009 Feb; 24(3):453-5. PubMed ID: 19133663
[TBL] [Abstract][Full Text] [Related]
11. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients.
Iwasaki K; Satoh-Nakagawa T; Maruyama M; Monma Y; Nemoto M; Tomita N; Tanji H; Fujiwara H; Seki T; Fujii M; Arai H; Sasaki H
J Clin Psychiatry; 2005 Feb; 66(2):248-52. PubMed ID: 15705012
[TBL] [Abstract][Full Text] [Related]
12. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
Lee JG; Shin BS; Lee YC; Park SW; Kim YH
Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
[TBL] [Abstract][Full Text] [Related]
14. Minocycline as adjunctive therapy for schizophrenia: an open-label study.
Miyaoka T; Yasukawa R; Yasuda H; Hayashida M; Inagaki T; Horiguchi J
Clin Neuropharmacol; 2008; 31(5):287-92. PubMed ID: 18836347
[TBL] [Abstract][Full Text] [Related]
15. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol.
Sa AR; Hounie AG; Sampaio AS; Arrais J; Miguel EC; Elkis H
Compr Psychiatry; 2009; 50(5):437-42. PubMed ID: 19683614
[TBL] [Abstract][Full Text] [Related]
16. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
[TBL] [Abstract][Full Text] [Related]
17. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients.
Shiloh R; Schapir L; Bar-Ziv D; Stryjer R; Konas S; Louis R; Hermesh H; Munitz H; Weizman A; Valevski A
Eur Neuropsychopharmacol; 2009 Sep; 19(9):654-8. PubMed ID: 19493658
[TBL] [Abstract][Full Text] [Related]
18. Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.
Rossi A; Bagalà A; Del Curatolo V; Scapati F; Bernareggi MM; Giustra MG;
Hum Psychopharmacol; 2009 Oct; 24(7):574-83. PubMed ID: 19790173
[TBL] [Abstract][Full Text] [Related]
19. Shiatsu as an adjuvant therapy for schizophrenia: an open-label pilot study.
Lichtenberg P; Vass A; Ptaya H; Edelman S; Heresco-Levy U
Altern Ther Health Med; 2009; 15(5):44-6. PubMed ID: 19771930
[TBL] [Abstract][Full Text] [Related]
20. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
